Overview

Financials

News Ideas Discussions Technicals Forecast Seasonals Options

SNDX fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

‪906.94 M‬USD

—

−3.87USD

2005

270

Michael A. Metzger

syndax.com

About

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Ownership

‪‪86.05 M‬‬

Free Float shares

‪‪82.47 M‬‬ (95.84%)

Closely held shares

‪‪3.58 M‬‬ (4.16%)

Free Float shares

‪‪82.47 M‬‬ (95.84%)

Closely held shares

‪‪3.58 M‬‬ (4.16%)

Capital structure

Market cap

‪‪906.94 M‬‬

Debt

‪‪345.63 M‬‬

Cash & equivalents

‪‪512.20 M‬‬

Enterprise value

‪‪740.37 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary

‪‪906.94 M‬‬

Price to earning ratio (P/E)

—

Price to sales ratio (P/S)

20.93x

Market Cap

Net income

Revenue

Price to earning ratio (P/E)

—

Price to sales ratio (P/S)

20.93x

Valuation ratios

Q1 '24

Q2 '24

Q3 '24

Q4 '24

Q1 '25

‪0.00‬

‪130.00‬

‪260.00‬

‪390.00‬

‪520.00‬

P/S

Growth and Profitability

Company’s recent performance and margins

Performance

‪−2,000.0%‬

‪−1,600.0%‬

‪−1,200.0%‬

‪−800.0%‬

‪−400.0%‬

Q1 '24

Q2 '24

Q3 '24

Q4 '24

Q1 '25

‪‪−105.00 M‬‬

‪‪−70.00 M‬‬

‪‪−35.00 M‬‬

‪0.00‬

‪‪35.00 M‬‬

Revenue

Net income

Net margin %

Revenue to profit conversion

Revenue

COGS

Gross profit

Op expenses

Op income

Non-Op income/ expenses

Taxes & Other

Net income

‪‪−90.00 M‬‬

‪‪−60.00 M‬‬

‪‪−30.00 M‬‬

‪0.00‬

‪‪30.00 M‬‬

Revenue

COGS

Gross profit

Expenses & adjustments

Net income

‪‪−90.00 M‬‬

‪‪−60.00 M‬‬

‪‪−30.00 M‬‬

‪0.00‬

‪‪30.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business

Period: 2024

Syndax Pharmaceuticals

By country

Period: 2024

United States

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue

Q2 '24

Q3 '24

Q4 '24

Q1 '25

Q2 '25

‪0.00‬

‪‪9.00 M‬‬

‪‪18.00 M‬‬

‪‪27.00 M‬‬

‪‪36.00 M‬‬

Actual

Estimate

Earnings

Next:Aug 11, 2025

Q2 '24

Q3 '24

Q4 '24

Q1 '25

Q2 '25

‪−1.40‬

‪−1.05‬

‪−0.70‬

‪−0.35‬

‪0.00‬

Actual

Estimate

Dividends

Dividend yield, history and sustainability

No dividends

SNDX has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company

Debt level and coverage

Q1 '24

Q2 '24

Q3 '24

Q4 '24

Q1 '25

‪‪−120.00 M‬‬

‪0.00‬

‪‪120.00 M‬‬

‪‪240.00 M‬‬

‪‪360.00 M‬‬

Debt

Free cash flow

Cash & equivalents

Financial position analysis

Short term

Long term

‪0.00‬

‪‪150.00 M‬‬

‪‪300.00 M‬‬

‪‪450.00 M‬‬

‪‪600.00 M‬‬

Assets

Liabilities